These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 10407253)
1. Estimation of the treatment effect in a clinical trial when recurrent events define the endpoint. Mahé C; Chevret S Stat Med; 1999 Jul; 18(14):1821-9; discussion 1831. PubMed ID: 10407253 [TBL] [Abstract][Full Text] [Related]
3. Analysis of multiple failure time data from an AIDS clinical trial. Finkelstein DM; Schoenfeld DA; Stamenovic E Stat Med; 1997 Apr; 16(8):951-61. PubMed ID: 9160491 [TBL] [Abstract][Full Text] [Related]
4. Analysis of recurrent failure times data: should the baseline hazard be stratified? Mahé C; Chevret S Stat Med; 2001 Dec; 20(24):3807-15. PubMed ID: 11782035 [TBL] [Abstract][Full Text] [Related]
5. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162 [TBL] [Abstract][Full Text] [Related]
6. Randomized, controlled trial of ibuprofen syrup administered during febrile illnesses to prevent febrile seizure recurrences. van Stuijvenberg M; Derksen-Lubsen G; Steyerberg EW; Habbema JD; Moll HA Pediatrics; 1998 Nov; 102(5):E51. PubMed ID: 9794981 [TBL] [Abstract][Full Text] [Related]
7. Analysis of recurrent events: a systematic review of randomised controlled trials of interventions to prevent falls. Donaldson MG; Sobolev B; Cook WL; Janssen PA; Khan KM Age Ageing; 2009 Mar; 38(2):151-5. PubMed ID: 19106254 [TBL] [Abstract][Full Text] [Related]
8. Power considerations for clinical trials using multivariate time-to-event data. Hughes MD Stat Med; 1997 Apr; 16(8):865-82. PubMed ID: 9160485 [TBL] [Abstract][Full Text] [Related]
9. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings. Chang LW; Harris J; Humphreys E Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of ribosomal fractions of Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and the membrane fraction of Kp (Ribomunyl) in the prevention of clinical recurrences of infectious rhinitis. Results of a multicenter double-blind placebo-controlled study. Serrano E; Demanez JP; Morgon A; Chastang C; Van Cauwenberge P Eur Arch Otorhinolaryngol; 1997; 254(8):372-5. PubMed ID: 9332892 [TBL] [Abstract][Full Text] [Related]
12. Influenza vaccine efficacy trials: a simulation approach to understand failures from the past. Benoit A; Legrand C; Dewé W Pharm Stat; 2015; 14(4):294-301. PubMed ID: 25924929 [TBL] [Abstract][Full Text] [Related]
13. First-event or marginal estimation of cause-specific hazards for analysing correlated multivariate failure-time data? Tai BC; De Stavola BL; de Gruttola V; Gebski V; Machin D Stat Med; 2008 Mar; 27(6):922-36. PubMed ID: 17551931 [TBL] [Abstract][Full Text] [Related]
14. Passive immunization for the treatment of HIV infection. Jacobson JM Mt Sinai J Med; 1998 Jan; 65(1):22-6. PubMed ID: 9458680 [TBL] [Abstract][Full Text] [Related]
15. Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trials. Flandre P; Pinçon C; Aboulker JP; Brun-Vézinet F; Pialoux G; Raffi F; Descamps D HIV Clin Trials; 2006; 7(3):116-24. PubMed ID: 16880168 [TBL] [Abstract][Full Text] [Related]
16. Tests for treatment group differences in the hazards for survival, before and after the occurrence of an intermediate event. Bebchuk JD; Betensky RA Stat Med; 2005 Feb; 24(3):359-78. PubMed ID: 15568187 [TBL] [Abstract][Full Text] [Related]
17. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen. Adis International Ltd Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591 [TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466 [TBL] [Abstract][Full Text] [Related]
19. A DAG-based comparison of interventional effect underestimation between composite endpoint and multi-state analysis in cardiovascular trials. Jahn-Eimermacher A; Ingel K; Preussler S; Bayes-Genis A; Binder H BMC Med Res Methodol; 2017 Jul; 17(1):92. PubMed ID: 28676086 [TBL] [Abstract][Full Text] [Related]
20. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types. Gilbert PB; Self SG; Ashby MA Biometrics; 1998 Sep; 54(3):799-814. PubMed ID: 9750238 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]